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Abstract
BACKGROUND: Most studies of CAD revascularization have been based on and reported
according to angiographic criteria which don’t consider the relation between the resulting effective
flow distal to the stenosis and the demand of a hypertrophied myocardial tissue.
MODEL: Mathematical model of the myocardial perfusion in comorbid CAD and ventricular
hypertrophy using Poiseuille’s law. The analysis yields that the curve, which represents the
relation between the perfusion and the severity of CAD depending on angiographic and/or
angiophysiologic criteria, is shifted to the right by the effect of myocardial tissue hypertrophy.
The right shift of said curve, which is directly proportional to the degree of ventricular
hypertrophy, indicates that the perfusion of the corresponding myocardial tissue is compromised
at angiographically and/or angiophysiologically subsignificant stenosis of the supplying epicardial
vessel.
RESULTS: Patients with comorbid CAD and left ventricular hypertrophy are more sensitive to
CAD-related hemodynamic changes. They are more prone to develop ischemic complications, than
their peers with isolated CAD regarding the same degree of coronary stenosis.
CONCLUSION: Patients with comorbid CAD and ventricular hypertrophy suffer from myocardial
hypoperfusion at angiographically and/or angiophysiologically subcritical epicardial stenosis.
Accordingly; the comorbidity of both diseases should be considered upon designing of the
treatment regime.
Background
Combined coronary artery disease and ven-
tricular hypertrophy are not uncommon; they
both share hypertension, which affects ∼ 26%
of the world population [1], as a risk factor.
Accumulation of atheromatous plaques under
tunica intima of the epicardial arteries restricts
the blood flow to the supplied cardiac tissue.
Chronic high-grade narrowing of the coronary
arteries induces subendocardial ischemia
during the escalation of the myocardial oxygen
demand throughout exercise or stress [2].
The strained myocytes release mediators like
adenosine and bradykinin [3][4] which in ad-
dition to stimulating coronary vasodilatation,
irritate the nerve endings leading to anginal
pain [5].
The treatment strategy for treating CAD
aims to improve survival and/or relieve
symptoms [6] including dyspnea and stable
angina pectoris. Said strategy usually involves
anti-anginal medications and/or PCI, or CABG
in case of complex CAD and/or left main
involvement, for achieving those aims. Trials
show that revascularization by PCI or CABG is
more effective than a strategy of medical ther-
apy alone, in relieving symptoms like angina
and dyspnea. Besides; it improves the quality
of life by reducing the use of anti-angina drugs
and increasing exercise capacity [7][8][9][10].
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However; studies indicate that PCI, as an initial
management strategy in patients with stable
coronary artery disease, did not reduce the
risk of complications as myocardial infarction
or other major cardiovascular events when
added to optimal medical therapy [11][12][13].
The guidelines recommend that ad hoc
PCI should not automatically be applied
after angiography [14]; and emphasize the
usefulness of optimal medical treatment for
selected patients, which can reduce angina
and the risk of myocardial infarction and
stroke substantially and prevent progression
of atherosclerosis in the entire vasculature.
Consequently; the clinical decisions for man-
agement of CAD generally need to balance
adherence to guidelines against judgments
based on specific patient, operator, social,
economic, and cultural factors [15]. Generally;
PCI and medical therapy should be viewed as
complementary, rather than opposing, strate-
gies [16]. Patients with stable coronary artery
disease and functionally significant stenoses,
benefit from the combination therapy of PCI
plus optimal medical therapy by showing
greater symptomatic improvement [17] and
decreased the need for urgent revasculariza-
tion. However; in patients without ischemia,
the outcome appeared to be favorable with the
optimal medical therapy alone [18].
For revascularization decisions and recom-
mendations; said significant stenosis has been
defined by most studies of CAD revasculariza-
tion, which have been based on and reported
according to angiographic criteria, as ≥ 70% di-
ameter narrowing, and/or ≥ 50% for left main
CAD [19]. Besides; angiophysiological crite-
rion, such as an assessment of fractional flow
reserve (FFR), has been used in deciding when
revascularization is indicated. Thus, for recom-
mendations about revascularization, coronary
stenosis with FFR ≤ 0.8 is also considered to be
significant [20]. The standard values provided
by both methods, and so the revascularization
decision, don’t consider the relation between
the resulting effective flow distal to the stenosis
and the demand of a comorbid hypertrophied
myocardial tissue.
Model
Hagen-Poiseuille law, which is an analytical so-
lution to the Navier-Stokes equation [21], states
that; the flow rate Q through a coronary vessel
is directly proportional to the pressure gradi-
ent ∆P between the aortic root and the right
atrium; and inversely proportional to the resis-
tance R within the vessel. Wherein; the resis-
tance R is inversely proportional to the radius α
of the vessel elevated to the fourth power, and
is directly proportional to the blood viscosity
µ and the vessel length ∆l. So, by considering
a circular cross-section of the vessel:
Q = ∆P
piα4
8µ∆l
when
R =
8µ∆l
piα4
so;
Q ∝
1
R
∝ α4 ∝
1
∆l
The blood flow, which is a non-Newtonian
fluid, within the circulation doesn’t imitate
precisely this law [22], because said relation
is applied on a Newtonian fluid in the
steady laminar flow moving through a long
cylindrical pipe. Still, the law outlines the
dominant determinants which influence the
blood flow Q within the vasculature either in
physiological or pathological conditions.
Atherosclerosis commonly affects the epicar-
dial coronary vessels leading to narrowing of
the vessel caliber αe and increase vascular re-
sistance of the supplying vessel Re. While:
Re ∝
1
α4e
the corresponding supplied myocardial seg-
ment doesn’t actually suffer this severe blood
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flow reduction indicated in the above equation.
The vasculature of the coronary circulation is
arranged in-series, in addition to the in-parallel
arrangement, so that the epicardial vascular re-
sistance Re is a segmental resistance. The coro-
nary circulation can be divided into two com-
partments, the large epicardial conduit vessels
and the resistance vessels, which are typically
less than 300µm in diameter [23]. Whereas the
conduit vessels exert little if any resistance to
flow, resistance to flow progressively rises as
the vessel diameter of the resistance vessels de-
clines from about 300µm in the small arteries
to less than 100µm in the arteriolar vessels [24].
Therefore; the total resistance to blood flow R
comprises mainly the pre-capillary resistance
Rc, the resistance of microvasculature Rm, and
the negligible resistance of the epicardial or
conductance vessels Re.
R = Rc + Rm + Re
Narrowing of the radius of the epicardial ves-
sel, due to atheromatous plaque, will increase
the resistance in this vessel; but as:
Rc + Rm  Re
the impact of mild to moderate increase of
the epicardial resistance Re on the overall
resistance of the coronary circulation R is
insignificant.
However; in case of combined coronary
artery disease and ventricular hypertrophy,
both Re and Rc + Rm are increased. Microan-
giogenesis is activated during the pathogenesis
of ventricular hypertrophy as a compensatory
mechanism to maintain effective blood supply
to the hypertrophied tissue. Accordingly; CAD
causes an increase in Re due to epicardial ar-
terial stenosis and ventricular hypertrophy in-
creases Rc + Rm due to neomicroangiogenesis,
i.e. addition of a new microvascular segment.
Rc+m ∝
1
α4m
∝ ∆l
consequently; the flow rate Q, and so the
perfusion of myocardial tissue, diminish
significantly upon subcritical stenosis of
the supplying epicardial artery during the
pathogenesis of CAD.
As mentioned; the identification of clinically-
significant stenosis of an epicardial artery de-
pends on an angiographic criterion, its radius
αe, and/or an angiophysiologic criterion, the
FFR, which is an absolute number result from
the ratio of the pressure distal to the lesion,
to the pressure proximal to the lesion during
induced hyperemia [20]. The graphical repre-
sentation of the relation between both these
criteria of the supplying artery and the perfu-
sion of the supplied myocardial tissue follows
a direct proportional relationship represented
by a sigmoid-shaped curve, due to the effect
of segmental resistance. Myocardial perfusion
ξ describes the blood flow Q in ml/min per
cubic centimeter of cardiac muscle volume V.
ξ =
Q
V
According to the relation between the radius
αe of an epicardial coronary artery, as an
angiographic criterion, and the perfusion ξ of
the corresponding supplied myocardial tissue
represented in Figure 1; the perfusion ξ doesn’t
decrease significantly with gradual stenosis in
isolated CAD until a critical stenotic value φα
is reached, wherein the perfusion collapses
relatively. Clinically; said critical value φα is
defined as ≥ 70% radius αe reduction, signifi-
cant stenosis [19]. However; in patients with
comorbid CAD and ventricular hypertrophy;
the curve is shifted to the right indicating
an increase in the critical stenotic value φα,
so that the perfusion ξ of the corresponding
supplied myocardial tissue collapses relatively
at a clinically subsignificant stenosis. The right
shift in said patients depends on the degree of
ventricular hypertrophy.
Additionally; the relation between another
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angiophysiologic criterion, the fractional flow
reserve FFR, within a stenotic epicardial artery
and the perfusion ξ of the corresponding
supplied myocardial tissue, as represented
in Figure 2, indicates that the perfusion ξ is
not meaningfully reduced with the gradual
decrease of FFR until a critical value φFFR is
reached, wherein the perfusion ξ collapses
relatively. Clinical trials defined said critical
value φFFR as a FFR ≤ 0.8 [25][26]. Though; in
patients with combined CAD and ventricular
hypertrophy; the curve shows a right shift,
which is directly proportional to the degree of
ventricular hypertrophy, indicating an increase
in the critical stenotic value φFFR, so that the
perfusion ξ of the corresponding supplied
myocardial tissue collapses relatively at a
clinically subsignificant reduction in the FFR.
The proposed model gives a more sensitive
formula to detect the critical stenosis, which
takes into account the demand of the supplied
bulky myocardium. The isolated CAD curve
is a logistic function; wherein x represents the
critical stenosis and k is the curve slope:
f (x) =
1
1 + e−kx
in patients with comorbid CAD and ventricular
hypertrophy; the curve is shifted to the right by
a yielding x8 as a representation of the critical
stenosis:
f (x) =
1
1 + e−k(x8−a)
then;
x8 = x + a
wherein the curve shift a is directly propor-
tional to the difference in muscle bulk ∆M
which obtained by Echocardiogram;
a ∝ ∆M
a = ω∆M
the value of the constant ω can be obtained ex-
perimentally. So; the percentage of the critical
patency in patients with comorbid CAD and
ventricular hypertrophy x8 is:
x8 = x + (ω∆M)
Results
Individuals with pathological ventricular
hypertrophy are more sensitive to haemody-
namic changes of the coronary circulation or
pathologies that reduce the coronary reserve.
Ventricular hypertrophy stresses the subendo-
cardial myotissue due to increase the structural
resistance of the coronary circulation. Said
stress is ameliorated by compensatory func-
tional changes to sustain the normal coronary
blood flow. Although during vigorous exercise,
the compensatory capability of the coronary
flow reserve is exhausted under the effect
of demand upsurge and shortened diastolic
period. Occasional hemodynamic disturbances
or subclinical pathologies which lessen the
maximum coronary reserve may lead to
selective subendocardial hypoperfusion.
Comorbid CAD and ventricular hypertro-
phy cause the subendocardial tissue to suffer,
during exercise or stress, from ischemia at
an angiographically subsignificant stenosis
in the supplying epicardial artery. CAD
primes the structural resistance of the neomi-
crovasculature of the hypertrophied tissue.
So; subcritical stenosis of the corresponding
epicardial artery, mainly due to atherosclerosis,
causes the total resistance to rise effectively to
reduce the flow rate and exhaust the reactive
compensatory mechanisms. The curve shift
to the right in said patients doesn’t affect the
risk of myocardial infarction, yet they are
more susceptible to and usually presented
by NSTEMI; with higher rates of transition
from ischemia to necrosis in the affected
hypertrophied endocardial tissue. Increased
muscle bulk shifts the endocardium away from
the main blood supply. Besides; subjection
to higher extravascular pressure depletes the
functional vasodilator reserve in long standing
pathological hypertrophy.
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Patients with combined CAD and ventricu-
lar hypertrophy have a higher risk to develop
arrhythmias than their peers who suffer from
isolated CAD. In pathological hypertrophy;
the neomicroangiogenesis shows anatomical
and architectural dysgenesis in relation to the
hypertrophied tissue. Said dysgenesis leads to
failure of the coronary bed to uniformly supply
the cardiac muscle, rendering foci within the
hypertrophied muscle bulk at greater risk of
ischemic injury. These stressed foci can be ar-
rhythmogenic upon increased cardiac demand
leading to serious arrhythmia and sudden car-
diac death.
Discussion
During cardiac catheterization; the main
determinants of revascularization therapy
in CAD patients, are either angiographic
or angiophysiological criteria, measured
during drug induced hyperemia, to identify
the clinically-significant stenosis. Said de-
terminants depend on the relation between
the size of the insinuated plaque and the
vascular diameter. A stenosis which reduces
the radius of the epicardial vessel by 70% is
considered significant angiographically. In
another determinant; a small sensor on the
tip of the guidewire is used to measure the
pressure, temperature and flow to determine
the exact severity of the lesion. The ratio
between the pressure distal to the lesion and
the pressure proximal to the lesion, which
is the fraction flow reserve FFR, measures
the pressure drop caused by the stenosis.
A fraction flow reserve value ≤ 0.8 defines
the stenosis to be significant. The FFR is a
better method to detect the physiological
significance of a stenosis [27], as it takes into
account collateral flow, which can render an
anatomical blockage functionally unimportant.
Also, standard angiography can underestimate
or overestimate narrowing, because it only
visualizes contrast inside a vessel. Yet; the
standard values provided by both methods to
identify a stenotic lesion as significant, don’t
consider the relation between the resulting
effective flow distal to the stenosis and the
demand of a hypertrophied myocardial tissue.
The pathogenesis of ventricular hypertrophy
implicates an increase in the number of
force-generating sarcomeres in the myocyte
[28]. According to La Place law; an increase
in pressure can be offset by an increase in
wall thickness [29]. This mechanical input
is transduced into a biochemical sequel that
modifies gene transcription in the nucleus.
The focal adhesion complex, in addition to
the G-coupled neurohormonal augmentation
[30], is proposed as the effector transducers of
said mechanical input [31]. Integrins connect
the internal cytoskeleton of the cell to the
extracellular matrix, wherein multiple tyrosine-
phosphorylated kinases and serine-threonine
kinases that are implicated in the signaling of
hypertrophy can be found in the ECM [32][33].
Angiogenesis is triggered during the
pathogenesis of myocardial hypertrophy by
increased cardiac work and oxygen demand;
in an attempt to normalize maximal my-
ocardial perfusion and capillary domains
to sustain oxygen delivery. A limitation
of capillary growth will increase diffusion
distance for oxygen, while inadequate ar-
teriolar growth will reduce maximal tissue
perfusion. Pathogenesis of hypertrophy is
categorized into pressure overload-induced,
volume overload-induced, thyroxin-induced
and exercise-induced models according to
the stimulus for increasing muscle bulk.
In exercise-induced and thyroxin-induced
models; angiogenesis and arteriogenesis are
well documented experimentally [34]. While
in other models; there is a considerable
variation in the reports of the literature about
the extent and pattern of angiogenesis and
the consequential coronary microvascular
resistance. The reasons for the discrepancy
between these studies are not evident, but the
duration of the hypertrophy and the specificity
of the stimulus may play a role.
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Mathematically; angiogenesis increases the
coronary microvascular resistance structurally,
due to the addition of a new microvascular
segment. However, in vivo; structural resis-
tance can be modulated by functional changes,
wherein autoregulatory adjustments involving
the vasodilator reserve may ameliorate said
structural resistance escalation. Well-trained
athletes with physiological cardiac hypertro-
phy show a proportional increase of cardiac
myocytes and coronary vasculature with
no change in the proportion of extracellular
collagen [35]. These structural modulations
are accompanied by functional adaptations
resulting in a compensatory exponential
coronary reserve and vasodilator capacity.
Functional adaptations can include changes
in neurohumoral control and changes in local
vascular control mechanisms [36][37]. In
pathological severe hypertrophy; pathological
features of the strained neoangiogenesis
halt the functional compensation for the
structural increase in the microvascular resis-
tance. Endothelium-dependent vasodilation is
markedly impaired in the coronary microves-
sels of patients with hypertension-induced
ventricular hypertrophy [38]. Accordingly;
severe ventricular hypertrophy is associated
with a reduction in coronary vascular reserve
[39].
Myocardial infarction is mainly caused
by rupture of vulnerable fibroatheromatous
plaque forming a thrombus that interferes
with myocardial blood supply leading to
excessive ischemia then necrosis [40]. Usually;
soft non-stenotic plaques are more susceptible
to rupture, causing major cardiovascular
events [41]. The vulnerability of the plaque
depends on lesion-specific characteristics
like thin fibrous cap, large lipid-rich necrotic
core, increased plaque inflammation, positive
vascular remodeling, increased vasa-vasorum
neovascularization, and intra-plaque hemor-
rhage [42]. Therefore; the comorbidity between
CAD and ventricular hypertrophy doesn’t
affect the risk of developing MI. However;
patients with said comorbid diseases have
higher rates of transition from ischemia to
necrosis in the affected endocardial tissue,
due to increase diffusion distance for oxygen
and exhaustion of the functional compensa-
tion. They are also more susceptible to and
usually presented by NSTEMI, due to the
sensitivity of the endocardial myotissue to the
equilibrium between the structural resistance
of microvasculature and the reactive functional
modulation.
Myocardial ischemia is characterized by
ionic and biochemical alterations, creating an
unstable electrical substrate capable of initi-
ating and sustaining arrhythmias [43]. Theo-
retically; onerous angiogenesis in pathological
hypertrophy shows patterns of anatomical and
architectural dysgenesis rendering foci within
the hypertrophied muscle bulk at greater risk
of ischemic injury. Said stressed foci acquire
different electrochemical properties, due to de-
fective function of ATPase-dependent pumps,
leading to tissue heterogeneity. Theses foci
become arrhythmogenic, especially with in-
creased cardiac demand during above-normal
exercise or severe stressful conditions, lead-
ing to functional re-entry. Hence; presence of
ventricular hypertrophy is associated with a
greater risk of sustained arrhythmias [44].
Conclusion
The mathematical model establishes that ven-
tricular hypertrophy increases the vascular
structural resistance of the coronary circulation
due to neomicroangiogenesis. Patients with
comorbid CAD and ventricular hypertrophy
suffer, due to exhaustion of functional compen-
sation, from complications of myocardial hy-
poperfusion at angiographically sub-significant
coronary artery stenosis. These patients are
more susceptible to NSTEMI, serious arrhyth-
mias and sudden cardiac death than patients
with isolated CAD. Upon confirmation of such
results by large investigational studies, said
results should be taken into account during de-
signing the treatment strategy of said patients.
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Figure 1: A graphical representation of the relation between the ratio of the perfusion of myocar-
dial tissue supplied by a stenotic epicardial coronary ξa, to the perfusion in case of
hypothetical absence of stenosis ξo; and the ratio of the radius of said stenotic artery
(αe)a, to the radius in case of hypothetical absence of stenosis (αe)o. Both ratios are
presented by absolute numbers. In isolated CAD; the direct proportional relationship
is represented by a sigmoid-shaped curve, wherein the perfusion of myocardial tissue
supplied by said stenotic epicardial coronary ξa collapse relatively at a critical stenotic
value φα. Comorbid CAD and ventricular hypertrophy shift the curve to the right leading
to an increase in the critical stenotic value φα.
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Figure 2: A graphical representation of the relation between the ratio of the perfusion of myocar-
dial tissue supplied by a stenotic epicardial coronary ξa, to the perfusion in case of
hypothetical absence of stenosis ξo; and FFR which is the ratio of the pressure distal to
the stenosis Pa, to the pressure proximal to the stenosis Po. Both ratios are presented by
absolute numbers. In isolated CAD; the direct proportional relationship is represented
by a sigmoid-shaped curve, wherein the perfusion of myocardial tissue supplied by
said stenotic epicardial coronary ξa collapse relatively at a critical stenotic value φFFR.
Comorbid CAD and ventricular hypertrophy shift the curve to the right leading to an
increase in the critical stenotic value φFFR.
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